Therapeutic Class Description: Immunomodulatory Agents

<table>
<thead>
<tr>
<th>Medication</th>
<th>Medication</th>
<th>Medication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actemra SQ</td>
<td>Ilumya</td>
<td>Siliq</td>
</tr>
<tr>
<td>Actemra Infusion</td>
<td>Inflectra Infusion</td>
<td>Simponi</td>
</tr>
<tr>
<td>Arcalyst</td>
<td>Kevzara</td>
<td>Simponi Aria Infusion</td>
</tr>
<tr>
<td>Avsola Infusion</td>
<td>Kineret</td>
<td>Skyrizi</td>
</tr>
<tr>
<td>Cimzia</td>
<td>Olumiant</td>
<td>Stelara</td>
</tr>
<tr>
<td>Cosentyx</td>
<td>Orenda Infusion</td>
<td>Stelara Infusion</td>
</tr>
<tr>
<td>Enbrel</td>
<td>Orenda SQ</td>
<td>Taltz</td>
</tr>
<tr>
<td>Enspryng</td>
<td>Otezla</td>
<td>Tremfya</td>
</tr>
<tr>
<td>Entyvio Infusion</td>
<td>Remicade Infusion</td>
<td>Uplizna</td>
</tr>
<tr>
<td>Humira</td>
<td>Renflexis</td>
<td>Xeljanz and Xeljanz XR</td>
</tr>
<tr>
<td>Ilaris</td>
<td>Rinvoq ER</td>
<td></td>
</tr>
</tbody>
</table>

**Eligible Beneficiaries**

NC Medicaid (Medicaid) beneficiaries shall be enrolled on the date of service and may have service restrictions due to their eligibility category that would make them ineligible for this service.

NC Health Choice (NCHC) beneficiaries, ages 6 through 18 years of age, shall be enrolled on the date of service to be eligible, and must meet policy coverage criteria, unless otherwise specified. **EPSDT does not apply to NCHC beneficiaries.**

**EPSDT Special Provision: Exception to Policy Limitations for Beneficiaries under 21 Years of Age**

**42 U.S.C. § 1396d(r) [1905(r) of the Social Security Act]**

Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) is a federal Medicaid requirement that requires the state Medicaid agency to cover services, products, or procedures for Medicaid beneficiaries under 21 years of age if the service is medically necessary health care to correct or ameliorate a defect, physical or mental illness, or a condition [health problem] identified through a screening examination (includes any evaluation by a physician or other licensed clinician). This means EPSDT covers most of the medical or remedial care a child needs to improve or maintain his/her health in the best condition possible, compensate for a health problem, prevent it from worsening, or prevent the development of additional health problems. Medically necessary services will be provided in the most economic mode, as long as the treatment made available is similarly efficacious to the service requested by the beneficiary’s physician, therapist, or other licensed practitioner; the determination process does not delay the delivery of the needed service; and the determination does not limit the beneficiary’s right to a free choice of providers. EPSDT does not require the state Medicaid agency to provide any service, product, or procedure

a. that is unsafe, ineffective, or experimental/investigational.
b. that is not medical in nature or not generally recognized as an accepted method of medical practice or
Service limitations on scope, amount, duration, frequency, location of service, and/or other specific criteria described in clinical coverage policies may be exceeded or may not apply as long as the provider’s documentation shows that the requested service is medically necessary “to correct or ameliorate a defect, physical or mental illness, or a condition” [health problem]; that is, provider documentation shows how the service, product, or procedure meets all EPSDT criteria, including to correct or improve or maintain the beneficiary’s health in the best condition possible, compensate for a health problem, prevent it from worsening, or prevent the development of additional health problems.

**EPSDT and Prior Approval Requirements**
If the service, product, or procedure requires prior approval, the fact that the beneficiary is under 21 years of age does **NOT** eliminate the requirement for prior approval.

**IMPORTANT ADDITIONAL INFORMATION** about EPSDT and prior approval is found in the NCTracks Provider Claims and Billing Assistance Guide, and on the EPSDT provider page. The Web addresses are specified below.

**NCTracks Provider Claims and Billing Assistance Guide:**
https://www.nctracks.nc.gov/content/public/providers/provider-manuals.html

**EPSDT provider page:**

**Health Choice Special Provision: Exceptions to Policy Limitations for Health Choice Beneficiaries ages 6 through 18 years of age**

**EPSDT does not apply to NCHC beneficiaries.** If a NCHC beneficiary does not meet the clinical coverage criteria within the **Outpatient Pharmacy prior approval** clinical coverage criteria, the NCHC beneficiary shall be denied services. Only services included under the Health Choice State Plan and the NC Medicaid clinical coverage policies, service definitions, or billing codes shall be covered for NCHC beneficiaries.

**Criteria**

1. **Ankylosing Spondylitis:** For Enbrel, Humira, Cosentyx, Aysola Cimzia, Inflectra, Simponi, Simponi Aria, Remicade, Taltz and Renflexis ONLY.
   - Beneficiary has a diagnosis of Ankylosing Spondylitis.
   - Beneficiary is not on another injectable biologic immunomodulator.
   - Beneficiary has been considered and screened for the presence of latent tuberculosis infection.
   - Beneficiary has been tested with Hep B SAG and Core Ab.
   - Beneficiary has experienced inadequate symptom relief from treatment with at least two NSAIDS.
   - Beneficiary is unable to receive treatment with NSAIDS due to contraindications.

10/01/2021
Systemic Immunomodulators

1. **Beneficiary has clinical evidence of severe or rapidly progressing disease.**
   AND
2. **Coverage of non-preferred medications require a trial and failure of Cosentyx, Enbrel or Humira or a clinical reason beneficiary cannot try Cosentyx, Enbrel or Humira.**

2. **Crohn’s Disease (Adult):** For Humira, Avasola, Cimzia, Entyvio, Inflectra, Stelara, Stelara Infusion Remicade and Renflexis ONLY.
   • Beneficiary has a diagnosis of moderate to severe Crohn’s Disease.
     AND
   • Beneficiary is not on another injectable biologic immunomodulator.
     AND
   • Beneficiary has been considered and screened for the presence of latent tuberculosis infection.
     AND
   • Beneficiary has been tested with Hep B SAG and Core Ab.
     AND
   • Coverage of non-preferred medications require a trial and failure of Humira or a clinical reason beneficiary cannot try Humira.

3. **Crohn’s Disease (Pediatric):** For Humira, Avasola, Inflectra, Remicade, and Renflexis ONLY
   • Beneficiary has a diagnosis of moderate to severe Crohn’s Disease.
     AND
   • Beneficiary is not on another injectable biologic immunomodulator.
     AND
   • Beneficiary has been considered and screened for the presence of latent tuberculosis infection.
     AND
   • Beneficiary has been tested with Hep B SAG and Core Ab.
     AND
   • Coverage of non-preferred medications require a trial and failure of Humira or a clinical reason beneficiary cannot try Humira.

4. **Polyarticular Juvenile Idiopathic Arthritis (PJIA):** For Enbrel, Humira, Actemra SQ, Actemra Infusion, Simponi Aria, Orecia Infusion, Orecia SQ, and Xeljanz ONLY.
   • Beneficiary has a diagnosis of Polyarticular Juvenile Idiopathic Arthritis.
     AND
   • Beneficiary is not on another injectable biologic immunomodulator.
     AND
   • Beneficiary has been considered and screened for the presence of latent tuberculosis infection.
     AND
   • Beneficiary has been tested with Hep B SAG and Core Ab.
     AND
   • Beneficiary has tried one systemic corticosteroid (e.g. prednisone, methylprednisolone) or methotrexate, leflunomide or sulfasalazine with inadequate response or is unable to take these therapies due to contraindications.
     OR
   • Beneficiary has PJIA subtype enthesitis related arthritis.
     AND
NC Medicaid Medicaid and Health Choice
Outpatient Pharmacy Effective Date: August 15, 2014
Prior Approval Criteria Amended Date: October 1, 2021
Systemic Immunomodulators

- Coverage of non-preferred medications require a trial and failure of Enbrel or Humira or a clinical reason beneficiary cannot try Enbrel or Humira.

5. **Systemic Onset Juvenile Idiopathic Arthritis (SJIA):** For Actemra Infusion, Actemra SQ and Ilaris ONLY.
   - Beneficiary has a diagnosis of Systemic Juvenile Idiopathic Arthritis.
   - Beneficiary is not on another injectable biologic immunomodulator.
   - Beneficiary has a diagnosis of Systemic Juvenile Idiopathic Arthritis.
   - Beneficiary has been considered and screened for the presence of latent tuberculosis infection.
   - Beneficiary has been tested with Hep B SAG and Core Ab.
   - Beneficiary has systemic arthritis with active systemic features and features of poor prognosis, as determined by the prescribing physician (e.g. arthritis of the hip, radiographic damage).

6. **Neonatal Onset Multisystem Inflammatory Disease (NOMID):** For Kineret ONLY.
   - Beneficiary has a diagnosis of neonatal-onset multisystem inflammatory disease.
   - Beneficiary is not on another injectable biologic immunomodulator.
   - Beneficiary has been considered and screened for the presence of latent tuberculosis infection.
   - Beneficiary has been tested with Hep B SAG and Core Ab.

7. **Cryopyrin-Associated Periodic Syndromes (CAPS) including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS):** For Ancryst and Ilaris ONLY.
   - Beneficiary has a diagnosis of Cryopyrin-Associated Periodic Syndromes (CAPS) including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS).
   - Beneficiary is not on another injectable biologic immunomodulator.
   - Beneficiary has been considered and screened for the presence of latent tuberculosis infection.
   - Beneficiary has been tested with Hep B SAG and Core Ab.

8. **Plaque psoriasis (Pediatric):** For Enbrel, Stelara (ages 6 and up), and Taltz (ages 6 and up) ONLY.
   - Beneficiary has a diagnosis of plaque psoriasis and is a candidate for systemic therapy or phototherapy.
   - Beneficiary is not on another injectable biologic immunomodulator.
   - Beneficiary has been considered and screened for the presence of latent tuberculosis infection.
Systemic Immunomodulators

- Beneficiary has been tested with Hep B SAG and Core Ab.
  AND
- Beneficiary has experienced a therapeutic failure/inadequate response with or has a contraindication or intolerance to methotrexate.
  AND
- Beneficiary has body surface area (BSA) involvement of at least 3%.
  OR
- Beneficiary has involvement of the palms, soles, head and neck, or genitalia, causing disruption in normal daily activities and/or employment.
  AND
- For ages 6 and up, coverage of non-preferred medications requires a trial and failure of Enbrel or a clinical reason beneficiary cannot try Enbrel.

9. **Plaque psoriasis (adult):** For Enbrel, Humira, Cosentyx, Avsola, Cimzia, Inflectra, Otezla, Remicade, Renflexis, Siliq, Skyrizi, Stelara, Taltz, and Tremfya ONLY.
   - Beneficiary has a documented definitive diagnosis of moderate-to-severe Chronic Plaque Psoriasis
     AND
   - Beneficiary is 18 years of age or older.
     AND
   - Beneficiary is not on another injectable biologic immunomodulator.
     AND
   - Beneficiary has been considered and screened for the presence of latent tuberculosis infection (not required for Otezla).
     AND
   - Beneficiary has been tested with Hep B SAG and Core Ab (not required for Otezla).
     AND
   - Beneficiary has body surface area (BSA) involvement of at least 3%.
     OR
   - Beneficiary has involvement of the palms, soles, head and neck, or genitalia, causing disruption in normal daily activities and/or employment.
     AND
   - Beneficiary has failed to respond to, or has been unable to tolerate phototherapy and ONE of the following medications or beneficiary has contraindications to these treatments:
     - Sotriatane (acitretin)
     - Methotrexate
     - Cyclosporine
     AND
   - Coverage of non-preferred medications require a trial and failure of Cosentyx, Enbrel or Humira or a clinical reason beneficiary cannot try either Cosentyx, Enbrel or Humira.
     AND
   - Beneficiaries, Providers, and Pharmacies utilizing Siliq must be registered appropriately in the Siliq Risk Evaluation and Mitigation Strategy Program (REMS program).

10. **Psoriatic arthritis:** For Enbrel, Humira, Cosentyx, Avsola, Cimzia, Inflectra, Orencia SQ, Orencia Infusion, Otezla, Renflexis, Remicade, Simponi, Simponi Aria, Stelara, Taltz, Tremfya, Xeljanz and Xeljanz XR ONLY
   - Beneficiary has a documented definitive diagnosis of Psoriatic Arthritis.
AND

- Beneficiary is 18 years of age or older (OR 2 years or older for Simponi Aria).
- Beneficiary is not on another injectable biologic immunomodulator.
- Beneficiary has been considered and screened for the presence of latent tuberculosis infection (not required for Otezla).
- Beneficiary has been tested with Hep B SAG and Core Ab (not required for Otezla).
- Beneficiary has a documented inadequate response or inability to take methotrexate.
- Coverage of non-preferred medications require a trial and failure of Cosentyx, Enbrel or Humira or a clinical reason beneficiary cannot try either Cosentyx, Enbrel or Humira.

11. Rheumatoid arthritis: For Enbrel, Humira, Actrema Infusion, Actemra SQ, Avsola,Cimzia, Inflectra, Kevzara, Kineret, Olumiant, Orencia, Orencia SQ, Remicade, Renflexis, Rinvoq ER, Simponi, Simponi Aria, Xeljanz and Xeljanz XR ONLY
   - Beneficiary has a diagnosis of Rheumatoid Arthritis.
   - Beneficiary is not on another injectable biologic immunomodulator.
   - Beneficiary has been considered and screened for the presence of latent tuberculosis infection.
   - Beneficiary has been tested with Hep B SAG and Core Ab.
   - Beneficiary has experienced a therapeutic failure/inadequate response with methotrexate or at least one disease modifying antirheumatic drug (e.g. leflunomide, hydroxychloroquine, minocycline, sulfasalazine).
   OR
   - Beneficiary is unable to receive methotrexate or disease modifying antirheumatic drug due to contraindications or intolerabilities.
   OR
   - Beneficiary has clinical evidence of severe or rapidly progressing disease.
   AND
   - Coverage of non-preferred medications require a trial and failure of Enbrel or Humira or a clinical reason beneficiary cannot try either Enbrel or Humira.

12. Ulcerative colitis (Adult): For Humira, Avsola, Entyvio, Inflectra, Remicade, Renflexis, Stelara, Simponi, Xeljanz and Xeljanz XR ONLY.
    - Beneficiary has a diagnosis of ulcerative colitis.
    - Beneficiary is not on another injectable biologic immunomodulator.
    - Beneficiary has been considered and screened for the presence of latent tuberculosis infection.
    - Beneficiary has been tested with Hep B SAG and Core Ab.
13. **Ulcerative colitis (Pediatric)**: For Avsola, Remicade ONLY
   - Beneficiary has a diagnosis of ulcerative colitis.  
     AND
   - Beneficiary is not on another injectable biologic immunomodulator.  
     AND
   - Beneficiary has been considered and screened for the presence of latent tuberculosis infection.  
     AND
   - Beneficiary has been tested with Hep B SAG and Core Ab.

14. **Hidradenitis Suppurativa**: For Humira ONLY (ages 12 and older)
   - Beneficiary has a diagnosis of Hidradenitis Suppurativa (moderate to severe).  
     AND
   - Beneficiary is not on another injectable biologic immunomodulator.  
     AND
   - Beneficiary has been considered and screened for the presence of latent tuberculosis infection.  
     AND
   - Beneficiary has been tested with Hep B SAG and Core Ab.

15. **Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS)**: Ilaris ONLY
   - Beneficiary has a diagnosis of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS).  
     AND
   - Beneficiary is not on another injectable biologic immunomodulator.  
     AND
   - Beneficiary has been considered and screened for the presence of latent tuberculosis infection.  
     AND
   - Beneficiary has been tested with Hep B SAG and Core Ab.

16. **Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD)**: Ilaris ONLY
   - Beneficiary has a diagnosis of Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD).  
     AND
   - Beneficiary is not on another injectable biologic immunomodulator.  
     AND
   - Beneficiary has been considered and screened for the presence of latent tuberculosis infection.  
     AND
   - Beneficiary has been tested with Hep B SAG and Core Ab.

17. **Familial Mediterranean Fever (FMF)**: Ilaris ONLY
   - Beneficiary has a diagnosis of Familial Mediterranean Fever (FMF).  
     AND
   - Beneficiary is not on another injectable biologic immunomodulator.
AND
- Beneficiary has been considered and screened for the presence of latent tuberculosis infection.
  AND
- Beneficiary has been tested with Hep B SAG and Core Ab.

18. **Non-infectious Intermediate Posterior Panuveitis:** Humira ONLY (ages 2 and older)
- Beneficiary has a diagnosis of Non-infectious Intermediate Posterior Panuveitis.
  AND
- Beneficiary is not on another injectable biologic immunomodulator.
  AND
- Beneficiary has been considered and screened for the presence of latent tuberculosis infection.
  AND
- Beneficiary has been tested with Hep B SAG and Core Ab.

19. **Giant Cell Arteritis:** Actemra and Actemra SQ ONLY
- Beneficiary has a diagnosis of Giant Cell Arteritis.
  AND
- Beneficiary is not on another injectable biologic immunomodulator.
  AND
- Beneficiary has been considered and screened for the presence of latent tuberculosis infection.
  AND
- Beneficiary has been tested with Hep B SAG and Core Ab.

20. **Cytokine Release Syndrome:** Actemra and Actemra SQ ONLY
- Beneficiary has a diagnosis of Cytokine Release Syndrome.
  AND
- Beneficiary is not on another injectable biologic immunomodulator.
  AND
- Beneficiary has been considered and screened for the presence of latent tuberculosis infection.
  AND
- Beneficiary has been tested with Hep B SAG and Core Ab.

21. **Non-Radiographic Axial Spondyloarthritis:** Cimzia, Cosentyx, and Taltz ONLY
- Beneficiary has a diagnosis of Non-Radiographic Axial Spondyloarthritis.
  AND
- Beneficiary is not on another injectable biologic immunomodulator.
  AND
- Beneficiary has failed an adequate trial of a Non-Steroidal Anti-Inflammatory Drug (NSAID) unless contraindicated.
  AND
- Beneficiary has been considered and screened for the presence of latent tuberculosis infection.
  AND
- Beneficiary has been tested with Hep B SAG and Core Ab.
  AND
- Coverage of non-preferred medications require a trial and failure of Cosentyx.

22. **Oral Ulcers associated with Behcet’s Disease:** Otezla ONLY
• Beneficiary has a documented diagnosis of Behcet’s disease.
  AND
• Beneficiary is 18 years of age or older.
  AND
• Beneficiary is not on another injectable biologic immunomodulator.

23. **Adult Onset Still’s Disease:** Ilaris ONLY
• Beneficiary has a diagnosis of Adult Onset Still’s Disease.
  AND
• Beneficiary is not on another injectable biologic immunomodulator.
  AND
• Beneficiary has been considered and screened for the presence of latent tuberculosis infection.
  AND
• Beneficiary has been tested with Hep B SAG and Core Ab.
  OR
• Beneficiary has systemic arthritis with active systemic features and features of poor prognosis, as determined by the prescribing physician (e.g. arthritis of the hip, radiographic damage).

24. **Neuromyelitis Optica Spectrum Disorder (NMOSD):** Uplizna and Enspryng
• Beneficiary has a diagnosis of Neuromyelitis Optica Spectrum Disorder.
  AND
• Beneficiary is anti-aquaporin-4 (AQP4) antibody positive.
  AND
• Beneficiary is 18 years of age or older.
  AND
• Beneficiary is not on another injectable biologic immunomodulator.
  AND
• Beneficiary has been considered and screened for the presence of latent tuberculosis infection.
  AND
• Beneficiary has been tested with Hep B SAG and Core Ab.

25. **Deficiency of Interleukin-1 Receptor Antagonist (DIRA):** Arcalyst and Kineret
• Beneficiary has diagnosis of Deficiency of Interleukin-1 Receptor Antagonist (DIRA).
  AND
• Beneficiary is not on another injectable biologic immunomodulator.
  AND
• Beneficiary has been considered and screened for the presence of latent tuberculosis infection.
  AND
• Beneficiary has been tested with Hep B SAG and Core Ab.
  AND
• For Arcalyst ONLY:
  o Agent is being used for maintenance of remission.
    AND
  o Beneficiary weighs at least 10kg.
### Systemic Immunomodulators

**Procedures**
- Approve for up to 12 months.
- Coverage of one injectable immunomodulator at a time.
# Systemic Immunomodulators

<table>
<thead>
<tr>
<th>Date of Change</th>
<th>Field</th>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/01/2021</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

- **Ankylosing Spondylitis**
- **Crohn’s Disease**
  - **(adult)**
  - **(pediatric)**
- **Polyarticular Juvenile Idiopathic Arthritis (PJIA)**
- **Systemic Onset Juvenile Idiopathic Arthritis (SJIA)**
- **Neonatal Onset Multisystem Inflammatory Disease (NOMID)**
- **Non-Radiographic Axial Spondyloarthritis**
- **Cryopyrin-Associated Periodic Syndromes (CAPS) including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS)**
- **Plaque Psoriasis**
  - **(pediatric)**
  - **(adult)**
- **Psoriatic Arthritis**
- **Rheumatoid Arthritis**
- **Ulcerative Colitis**
  - **(adult)**
  - **(pediatric)**
- **Hidradenitis Suppurativa**
- **Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS)**
### Systemic Immunomodulators

<table>
<thead>
<tr>
<th>Condition</th>
<th>Enbrel/P</th>
<th>Humira/P</th>
<th>Cosentyx/P</th>
<th>Actemra</th>
<th>Infusion/Actemra SQ</th>
<th>Arcalyst</th>
<th>Avsola</th>
<th>Cimzia</th>
<th>Enspryng</th>
<th>Entyvio</th>
<th>Ilaris</th>
<th>Ilumya</th>
<th>Inflectra</th>
<th>Kevzara</th>
<th>Kineret</th>
<th>Olumiant</th>
<th>Orencia/Perifosine</th>
<th>Orencia SQ</th>
<th>Otezla</th>
<th>Remicade</th>
<th>Renflexis</th>
<th>Rinvoq ER</th>
<th>Siliq</th>
<th>Simponi</th>
<th>Simponi Aria</th>
<th>Skyrizi</th>
<th>Stelara</th>
<th>Stelara Infusion</th>
<th>Taltz</th>
<th>Tremfya</th>
<th>Uplizna</th>
<th>Xeljanz/Xeljanz XR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Familial Mediterranean Fever (FMF)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Infectious Intermediate Posterior Panuveitis</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Giant Cell Arteritis</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cytokine Release Syndrome</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Behçet's Disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adult Still's Disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neuromyelitis Optica Spectrum Disorder (NMOSD)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deficiency of Interleukin-1 Receptor Antagonist (DIRA)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Trial and failure of Humira before coverage of non-preferred agent
**Trial and failure of Enbrel or Humira before coverage of non-preferred agent
***Trial and failure of either Cosentyx, Enbrel or Humira before coverage of non-preferred agent

10/01/2021 12
References

Updated September 2020.
27. Lilly, USA, LLC., Olumiant Prescribing Information. Indianapolis, IN: May 2018.
| 34. Viela Bio, Inc. Uplizna Prescribing Information. Gaithersburg, MD; June 2020. |
## Criteria Change Log

<table>
<thead>
<tr>
<th>Date</th>
<th>Change Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>08/15/2014</td>
<td>Criteria effective date</td>
</tr>
<tr>
<td>06/10/2015</td>
<td>add Otezla and add gcn 37262 for Humira</td>
</tr>
<tr>
<td>01/21/2016</td>
<td>add Cosentyx</td>
</tr>
<tr>
<td>06/13/2016</td>
<td>add dx Hidradenitis Suppurativa for Humira</td>
</tr>
<tr>
<td>10/03/2016</td>
<td>add Xeljanz XR</td>
</tr>
<tr>
<td>10/19/2016</td>
<td>add Taltz</td>
</tr>
<tr>
<td>06/27/2018</td>
<td>add diagnosis for Ilaris- Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), and Familial Mediterranean Fever (FMF) add Arcalyst to criteria coverage add infusion products to clinical coverage criteria-Actemra Infusion, Entyvio Infusion, Orencia Infusion, Remicade Infusion, Simponi Aria Infusion add new dx for Orencia- PHIA, Psoriatic Arthritis add Kevzara to criteria add diagnosis chart add Psoriatic Arthritis DX for coverage-Taltz add Psoriatic Arthritis DX for Xeljanz and Xeljanz XR</td>
</tr>
<tr>
<td>02/26/2019</td>
<td>update chart</td>
</tr>
<tr>
<td></td>
<td>add Simponi Aria for DX Ankylosing Spondylitis, add Enbrel PJIA</td>
</tr>
<tr>
<td></td>
<td>add Stelara Plaque Psoriasis (12 and up)</td>
</tr>
<tr>
<td></td>
<td>add Cimzia Plaque Psoriasis adult</td>
</tr>
<tr>
<td></td>
<td>add Otezla Psoriatic Arthritis</td>
</tr>
<tr>
<td></td>
<td>remove Renflexis exception</td>
</tr>
<tr>
<td></td>
<td>add Xeljanz/Xeljanx XR and Renflexis UC adults</td>
</tr>
<tr>
<td></td>
<td>add Actemra and Actemra SQ to Giant Cell Arteritis and Cytokine Release Syndrome</td>
</tr>
<tr>
<td></td>
<td>add Tremfya</td>
</tr>
<tr>
<td></td>
<td>add Olumiant</td>
</tr>
<tr>
<td>07/18/2019</td>
<td>add ages for Humira in HS (12 and older) and Uveitis (2 and older)</td>
</tr>
<tr>
<td></td>
<td>Include Cosentyx as try and fail for Ankylosing Spondylitis, Plaque Psoriasis, and Psoriatic Arthritis add Ilumya for Plaque Psoriasis (adult) update chart add Siliq</td>
</tr>
<tr>
<td>11/04/2019</td>
<td>Add Dx Non-Radiographic Axial Spondyloarthritis for Cimzia</td>
</tr>
<tr>
<td>12/09/2019</td>
<td>Removed GCN’s, add Skyrizi to adult plaque psoriasis, add Stelara Infusion</td>
</tr>
<tr>
<td>10/01/2021</td>
<td></td>
</tr>
<tr>
<td>Date</td>
<td>Changes</td>
</tr>
<tr>
<td>------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>07/13/2020</td>
<td>Added Taltz to Ankylosing Spondylitis, add Rinvoq ER</td>
</tr>
<tr>
<td></td>
<td>Added Behcet’s Disease for Otezla</td>
</tr>
<tr>
<td></td>
<td>Updated EPSDT Information</td>
</tr>
<tr>
<td></td>
<td>Updated table</td>
</tr>
<tr>
<td>02/01/2021</td>
<td>Add Stelara for ulcerative colitis for Adults</td>
</tr>
<tr>
<td></td>
<td>Add Xeljanz XR for ulcerative colitis for adults</td>
</tr>
<tr>
<td></td>
<td>Add contraindication or intolerance to methotrexate step for plaque psoriasis</td>
</tr>
<tr>
<td>02/01/2021</td>
<td>Add Taltz to plaque psoriasis for pediatrics &amp; Non-Radiographic Axial Spondyloarthritis</td>
</tr>
<tr>
<td></td>
<td>Add Avsola</td>
</tr>
<tr>
<td>02/01/2021</td>
<td>Added Cosentyx to Non-Radiographic Axial Spondyloarthritis</td>
</tr>
<tr>
<td></td>
<td>Added bullet to Non-Radiographic Axial Spondyloarthritis requiring t/f of Cosentyx prior to approval of NP agent</td>
</tr>
<tr>
<td></td>
<td>Added adult-onset Still’s disease (AOSD) criteria for Ilaris</td>
</tr>
<tr>
<td></td>
<td>Added Tremfya to psoriatic arthritis</td>
</tr>
<tr>
<td></td>
<td>Added Enspryng &amp; Uplinza for Neuromyelitis Optica Spectrum Disorder (NMOSD) to policy</td>
</tr>
<tr>
<td></td>
<td>Age for Stelara for pediatric plaque psoriasis changed from 12 to 6</td>
</tr>
<tr>
<td>02/01/2021</td>
<td>Added Simponi Aria &amp; Xeljanz to Polyarticular Juvenile Idiopathic Arthritis</td>
</tr>
<tr>
<td></td>
<td>Updated age for Simponi Aria for Psoriatic Arthritis</td>
</tr>
<tr>
<td>10/01/2021</td>
<td>Added Deficiency of Interleukin-1 Receptor Antagonist (DIRA) for Arcalyst and Kineret</td>
</tr>
</tbody>
</table>